Forte Biosciences, Inc. Cash Flow Statement
FBRX|2 years of annual SEC 10-K data (FY2018-FY2019)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$31M
FY2019
Free Cash Flow
-$32M
FY2019
Capital Expenditures
$655,000
Cash used for long-term assets
Dividends Paid
N/A
FY2019
Forte Biosciences, Inc. used $31M in operating cash flow and negative free cash flow of $32M in FY2019.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 |
|---|---|---|
| Net Income | -$38.9M | -$33.5M |
| Depreciation & Amortization | $292.0K | $255.0K |
| Operating Cash Flow | -$31.1M | -$29.5M |
| Capital Expenditures | $655.0K | $525.0K |
| Free Cash Flow | -$31.8M | -$30.1M |
| FCF Margin | -77531.7% | -61355.1% |